

CLAIMS

1. A method for examining kidney disease, which comprises detecting a fatty acid binding protein contained in a specimen collected from a mammal other than rodents, said fatty acid binding protein being derived from kidney tissue.

2. The examination method according to claim 1, wherein the fatty acid binding protein being derived from kidney tissue is a liver-type fatty acid binding protein.

3. The examination method according to claim 1, wherein the kidney tissue is tissue from the proximal tubule of the kidney.

4. The examination method according to claim 1, wherein the specimen is kidney tissue or urine.

5. The examination method according to claim 1, wherein the mammal other than rodents is human.

6. The examination method according to claim 1, which further comprises a process for comparing the test result with that of a control specimen collected from an animal having normal kidney tissue.

7. The examination method according to claim 1, wherein the detection of the fatty acid binding protein is carried out using an antibody specifically binding to said fatty acid binding protein.

Sub A8

00578693-000000

Sub A9

Sub A10

Sub A11

8. The examination method according to claim 7, wherein the antibody specifically binding to the fatty acid binding protein is an antibody specifically binding to a liver-type fatty acid binding protein.

9. The examination method according to claim 8, wherein the antibody specifically binding to the fatty acid binding protein is an antibody that substantially does not cross-react with a heart muscle-type fatty acid binding protein.

10. A method for examining kidney disease excluding α_{2u} -globulin nephropathy of rodent, which comprises detecting an α_{2u} -globulin or a fatty acid binding protein contained in a specimen collected from a rodent selected from rat and mouse, and further determining the decrease in the amount thereof with comparing it with that of a specimen from a normal animal, said fatty acid binding protein being derived from kidney tissue.

11. The examination method according to claim 10, wherein the fatty acid binding protein is a kidney-type fatty acid binding protein.

12. The examination method according to claim 10, wherein the specimen is kidney tissue, urine or blood.

13. The examination method according to claim 10, wherein the kidney diseases are an anti-GMB nephritis model.

14. A reagent or kit for examination, which is used

09578693-052600

Sub A12
C2

Sub A13
C3

in the examination method according to any one of claims 1-13.

15. The reagent or kit for examination according to claim 14, which contains an antibody specifically binding to a fatty acid binding protein.

5

*add A14**add C6*

009250" E6982550